NU SKIN ENTERPRISES, INC. NUS

Industrials SIC 5122 - Wholesale-Drugs, Proprietaries & Druggists' Sundries NAICS Wholesale Trade › Merchant Wholesalers, Nondurable Goods › Drugs and Druggists' Sundries Merchant Wholesalers derived NYSE

Nu Skin Enterprises, Inc. develops and distributes a comprehensive line of premium-quality beauty and wellness solutions in nearly 50 markets worldwide. In 2025, our revenue of

$1.5 billion was primarily generated by our two primary product categories: beauty products and wellness products. We operate in the direct selling channel, primarily utilizing person-to-person

marketing to promote and sell our products, including through the use of social and digital platforms.

synergistic and adjacent growth through our strategic investment arm known as Rhyz Inc., which we formed in 2018. Our Rhyz businesses primarily consist of consumer, technology and manufacturing companies. In 2025, the Rhyz companies generated

Last close 4.79 2026-10-23
Market cap $233.2M 2026-06-30 share count
52-week range 4.45 - 11.67

Valuation FY2025 figures against the last close

P/S0.2x
P/E1.5x
P/FCF5.1x
EV/EBITDA1.8x
Dividend yield5.1%
Diluted EPS3.18

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $1.49B$1.73B$1.97B$2.23B$2.70B$2.58B$2.42B$2.68B$2.28B$2.21B
Cost of revenue $453.8M$550.2M$611.9M$630.9M$675.2M$658.0M$581.4M$634.1M$502.1M$500.5M
Gross profit $1.03B$1.18B$1.36B$1.59B$2.02B$1.92B$1.84B$2.04B$1.78B$1.71B
R&D $10.8M$13.0M$22.6M$23.3M$27.2M$23.3M$30.1M$23.0M$22.0M$24.3M
SG&A $432.1M$479.0M$546.9M$555.8M$654.4M$636.5M$616.0M$662.3M$564.5M$554.2M
Total operating expenses $965.6M$1.33B$1.31B$1.48B$1.79B$1.67B$1.57B$1.80B$1.50B$1.48B
Operating income $65.8M-$151.6M$48.3M$110.8M$234.0M$257.6M$267.4M$240.9M$274.5M$231.1M
Interest expense $13.9M$26.4M$25.6M$13.5M$11.0M$13.1M$19.2M$21.8M$22.2M$15.6M
Pre-tax income $196.2M-$175.1M$26.6M$89.0M$232.5M$256.2M$255.2M$219.7M$265.6M$212.8M
Income tax $36.0M$28.5M$18.0M$15.8M$85.2M$64.9M$81.6M$97.8M$136.1M$69.8M
Net income $160.2M-$146.6M$8.6M$104.8M$147.3M$191.4M$173.6M$121.9M$129.4M$143.1M
EPS, basic 3.25-2.950.172.102.933.663.132.212.452.58
EPS, diluted 3.18-2.950.172.072.863.633.102.162.362.55
Shares, diluted (wtd. avg.) 50.3M49.7M49.9M50.5M51.4M52.8M55.9M56.5M54.9M56.1M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $238.6M$186.9M$256.1M$264.7M$339.6M$402.7M$335.6M$386.9M$426.4M$357.2M
Short-term investments $1.2M$11.1M$11.8M$13.8M$15.2M$21.2M$8.4M$11.3M$11.8M$10.9M
Receivables $39.5M$50.8M$58.7M$47.4M$41.3M$63.4M$50.4M———
Inventory $178.6M$190.2M$280.0M$346.2M$399.9M$314.4M$275.9M$295.8M$253.5M$249.9M
Total current assets $547.7M$538.6M$701.9M$759.9M$873.0M$903.2M$740.2M$799.2M$777.8M$714.3M
Property, plant and equipment $377.2M$379.6M$433.0M$444.8M$453.7M$468.2M$453.6M$464.5M$464.6M$444.7M
Goodwill $83.6M$83.6M$218.2M$206.4M$206.4M$203.0M$196.6M$196.6M$115.0M$115.0M
Other intangibles $42.6M$74.3M$95.3M$66.7M$77.0M$89.5M$80.3M$90.0M$67.6M$63.6M
Total assets $1.41B$1.47B$1.81B$1.82B$1.91B$1.96B$1.77B$1.69B$1.59B$1.47B
Accounts payable $26.2M$34.9M$43.1M$54.0M$50.0M$66.2M$39.0M$47.6M$50.3M$41.3M
Short-term debt $20.0M$30.0M$25.0M$25.0M$107.5M$30.0M$27.5M$69.5M$77.8M$82.7M
Total current liabilities $263.7M$296.6M$328.9M$359.2M$529.7M$542.9M$356.8M$439.7M$447.4M$399.0M
Long-term debt $204.2M$363.6M$478.0M$377.5M$268.8M$305.4M$334.5M$361.0M$310.8M$334.2M
Total liabilities $600.1M$817.5M$986.7M$923.7M$993.7M$1.06B$893.7M$912.6M$885.3M$810.0M
Retained earnings $1.86B$1.71B$1.87B$1.94B$1.91B$1.84B$1.73B$1.64B$1.61B$1.56B
Total equity $805.2M$651.5M$822.0M$897.3M$912.8M$894.3M$875.3M$781.9M$704.6M$664.1M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $80.3M$111.7M$118.6M$108.1M$141.6M$379.1M$177.9M$202.7M$302.6M$275.3M
Depreciation and amortisation $52.3M$69.8M$70.9M$72.5M$76.3M$74.0M$76.7M$83.0M$71.6M$72.4M
Stock-based compensation $24.1M$14.8M$15.6M$12.4M$23.2M$24.1M$9.9M$26.6M$19.3M$8.9M
Capital expenditure $34.3M$41.6M$58.5M$59.1M$68.6M$63.8M$66.1M$70.4M$60.2M$50.2M
Investing cash flow $170.7M-$38.0M-$134.5M-$67.1M-$88.7M-$79.4M-$71.4M-$108.8M-$92.0M-$57.9M
Financing cash flow -$202.4M-$133.2M$10.7M-$99.5M-$104.7M-$245.2M-$154.8M-$116.7M-$159.6M-$134.7M
Dividends paid $11.8M$11.9M$77.6M$77.0M$76.3M$78.4M$82.2M$80.6M$76.1M$78.4M
Buybacks $20.0M$0$13.0M$70.0M$80.4M$144.3M$825.0K$69.6M$71.7M$247.2M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-005130.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -1B 0 1B 2B 3B Revenue, FY2016: 2.2B Gross profit, FY2016: 1.7B Net income, FY2016: 143.1M Revenue, FY2017: 2.3B Gross profit, FY2017: 1.8B Net income, FY2017: 129.4M Revenue, FY2018: 2.7B Gross profit, FY2018: 2B Net income, FY2018: 121.9M Revenue, FY2019: 2.4B Gross profit, FY2019: 1.8B Net income, FY2019: 173.6M Revenue, FY2020: 2.6B Gross profit, FY2020: 1.9B Net income, FY2020: 191.4M Revenue, FY2021: 2.7B Gross profit, FY2021: 2B Net income, FY2021: 147.3M Revenue, FY2022: 2.2B Gross profit, FY2022: 1.6B Net income, FY2022: 104.8M Revenue, FY2023: 2B Gross profit, FY2023: 1.4B Net income, FY2023: 8.6M Revenue, FY2024: 1.7B Gross profit, FY2024: 1.2B Net income, FY2024: -146.6M Revenue, FY2025: 1.5B Gross profit, FY2025: 1B Net income, FY2025: 160.2M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $2.21B $2.28B $2.68B $2.42B $2.58B $2.70B $2.23B $1.97B $1.73B $1.49B
Gross profit $1.71B $1.78B $2.04B $1.84B $1.92B $2.02B $1.59B $1.36B $1.18B $1.03B
Net income $143.1M $129.4M $121.9M $173.6M $191.4M $147.3M $104.8M $8.6M -$146.6M $160.2M

Recent filings and events

  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Officer or director change Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Officer or director change Item 5.02
  • Results announced Item 2.02
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Officer or director change Item 5.02
  • Officer or director change Item 5.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 5122

TickerCompanyMarket capP/ERevenue growth
MCK MCKESSON CORP $116.68B 26.1x 12.4%
COR Cencora, Inc. $63.16B 41.6x 9.3%
CAH CARDINAL HEALTH INC $58.04B 34.5x 14.2%
HLF HERBALIFE LTD. $1.40B 6.1x 0.9%
COSM Cosmos Health Inc. $26.3M — 19.9%
HWH HWH International Inc. $20.7M — -30.8%
MEDS DataMeds AI, Inc. $6.8M — 28.7%
HKPD Cellyan Biotechnology Co., Ltd — — —